Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2021

View Archived Issues

AFYX Therapeutics presents preclinical data on anti-TNF antibody delivery through adhesive patch

Small-molecule OXS-7417 shows in vivo AML antitumoral effects

StemSynergy Therapeutics patents N-myc proto-oncogene protein inhibitors

Salk Institute, Sanford Burnham Prebys describe new ULK1 inhibitors

New PIKfyve inhibitors identified at AcuraStem

Discovery of novel antibiotic class of tethered macrocyclic peptides

Novel virulence factor LasB inhibitors for the treatment of P. aeruginosa infections

HA-344 shows promise for treating cutaneous metastatic melanoma

PearlRiverBio patents mutant EGFR/HER2 inhibitors

STM-2457: a first-in-class METTL3 inhibitor with preclinical proof of concept in AML models

Flamingo and Ionis expand alliance to develop RNA-targeted therapies for oncology

GRC-39815 shows efficacy in models of smoke-induced COPD

Vitalgenics reports preclinical findings with excindogen in PDAC

Twist collaborates with Boehringer Ingelheim on antibody research programs

KG207-M, a novel bifunctional fusion protein as disease-modifying therapy for AD

Platinum(II)-NHC complex targeting vimentin inhibits tumor metastasis

fMLP receptor promotes inflammatory brain injury

At WCLC, early steps towards success against SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...